ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 151 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $251,993 | -12.6% | 181,290 | 0.0% | 0.00% | -33.3% |
| Q1 2023 | $288,251 | -67.0% | 181,290 | +29.4% | 0.00% | -80.0% |
| Q4 2022 | $872,991 | -48.9% | 140,127 | -45.1% | 0.02% | -21.1% |
| Q3 2022 | $1,709,000 | -17.0% | 255,092 | -21.2% | 0.02% | -20.8% |
| Q2 2022 | $2,059,000 | +24.0% | 323,702 | -9.6% | 0.02% | +20.0% |
| Q1 2022 | $1,661,000 | -8.4% | 358,006 | -1.3% | 0.02% | 0.0% |
| Q4 2021 | $1,813,000 | -70.4% | 362,580 | +25.4% | 0.02% | -60.0% |
| Q2 2021 | $6,116,000 | -64.1% | 289,183 | -52.4% | 0.05% | -69.3% |
| Q1 2021 | $17,043,000 | +31.7% | 607,580 | +22.1% | 0.16% | +4.5% |
| Q4 2020 | $12,937,000 | -84.0% | 497,580 | -77.1% | 0.16% | -85.0% |
| Q3 2020 | $80,623,000 | -29.9% | 2,169,022 | -3.3% | 1.04% | -49.1% |
| Q2 2020 | $115,064,000 | +57.8% | 2,242,522 | -3.0% | 2.05% | +70.2% |
| Q1 2020 | $72,930,000 | -45.7% | 2,313,022 | +2.7% | 1.20% | -45.2% |
| Q4 2019 | $134,362,000 | +47.9% | 2,253,261 | -9.1% | 2.20% | +54.7% |
| Q3 2019 | $90,853,000 | -19.8% | 2,478,261 | +1.8% | 1.42% | +16.7% |
| Q2 2019 | $113,299,000 | +13.9% | 2,435,500 | -1.7% | 1.22% | -2.9% |
| Q1 2019 | $99,431,000 | -13.1% | 2,476,500 | -0.4% | 1.25% | +28.2% |
| Q4 2018 | $114,416,000 | +9.7% | 2,487,300 | +5.8% | 0.98% | +10.8% |
| Q3 2018 | $104,336,000 | +8.0% | 2,351,500 | -4.6% | 0.88% | +25.1% |
| Q2 2018 | $96,564,000 | -42.2% | 2,464,000 | +6.6% | 0.71% | -40.2% |
| Q1 2018 | $167,118,000 | +31.6% | 2,310,500 | +19.8% | 1.18% | +39.6% |
| Q4 2017 | $127,021,000 | +13.0% | 1,929,231 | -14.0% | 0.84% | -12.4% |
| Q3 2017 | $112,429,000 | +22.2% | 2,243,200 | +12.8% | 0.96% | +14.3% |
| Q2 2017 | $92,005,000 | +41.9% | 1,988,000 | +8.3% | 0.84% | +6.4% |
| Q1 2017 | $64,836,000 | +183.3% | 1,836,200 | +0.4% | 0.79% | +170.6% |
| Q4 2016 | $22,887,000 | +7.6% | 1,828,000 | +19.0% | 0.29% | +48.7% |
| Q3 2016 | $21,274,000 | +41.8% | 1,536,000 | +1.2% | 0.20% | -1.5% |
| Q2 2016 | $14,998,000 | -37.7% | 1,518,000 | +6.6% | 0.20% | +13.0% |
| Q1 2016 | $24,080,000 | -24.8% | 1,424,000 | -1.0% | 0.18% | -19.9% |
| Q4 2015 | $32,032,000 | -6.4% | 1,439,000 | -0.8% | 0.22% | -26.3% |
| Q3 2015 | $34,206,000 | -72.4% | 1,450,000 | -4.5% | 0.30% | -54.4% |
| Q2 2015 | $124,112,000 | +3.4% | 1,518,000 | +17.1% | 0.66% | -26.6% |
| Q1 2015 | $120,010,000 | +101.9% | 1,296,000 | -11.8% | 0.90% | +112.1% |
| Q4 2014 | $59,447,000 | +145.5% | 1,470,000 | +48.5% | 0.42% | +81.5% |
| Q3 2014 | $24,215,000 | +52.9% | 990,000 | -1.0% | 0.23% | +38.7% |
| Q2 2014 | $15,840,000 | +18.2% | 1,000,000 | +12.8% | 0.17% | -53.1% |
| Q1 2014 | $13,400,000 | +51.9% | 886,224 | +38.1% | 0.36% | +40.9% |
| Q4 2013 | $8,820,000 | +8.5% | 641,900 | +48.9% | 0.25% | +12.9% |
| Q3 2013 | $8,130,000 | – | 431,054 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |